Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells

Acquisition of drug resistance is one of the main obstacles encountered in cancer chemotherapy. Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. In addition, Northern-blot analysis revealed an eight fold upregulation of the imprinted H19 mRNA in R-HepG2 cells. H19 knockdown by transfection with antisense H19 oligonucleotides suppressed the MDR1/P-glycoprotein expression, increased the cellular doxorubicin accumulation level and sensitized doxorubicin toxicity in both HepG2 parent cells and R-HepG2 cells. Results from methylation-specific polymerase chain reaction analysis indicated that the MDR1 gene promoter was hypomethylated in R-HepG2 cells. Antisense H19 oligonucleotides transfection induced a marked increase in the percentage of MDR1 promoter methylation and decrease in MDR1 expression in R-HepG2 cells. Thus, the H19 gene is believed to induce P-glycoprotein expression and MDR1-associated drug resistance at least in liver cancer cells through regulation of MDR1 promoter methylation.

[1]  多田 靖弘.  MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment , 2002 .

[2]  P. Carroll,et al.  CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer , 2004, Cancer Research.

[3]  P. Heikkilä,et al.  Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[4]  A. Vercoutter-Edouart,et al.  Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA , 2002, Oncogene.

[5]  T. Dupressoir,et al.  Overexpression of an ectopic H 19 gene enhances the tumorigenic properties of breast cancer cells , 2002 .

[6]  S. Tilghman,et al.  Locus unlinked to alpha-fetoprotein under the control of the murine raf and Rif genes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Bruni,et al.  Developmentally regulated functions of the H19 differentially methylated domain. , 2003, Human molecular genetics.

[8]  Benjamin Tycko,et al.  Tumour-suppressor activity of H19 RNA , 1993, Nature.

[9]  S. Eddy.  Non–coding RNA genes and the modern RNA world , 2001, Nature Reviews Genetics.

[10]  H. Deckmyn,et al.  Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen. , 1998, Blood.

[11]  D. Gerhard,et al.  A fine-structure deletion map of human chromosome 11p: Analysis of J1 series hybrids , 1989, Somatic cell and molecular genetics.

[12]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[13]  T. Dupressoir,et al.  Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. , 2002, Carcinogenesis.

[14]  K. Ohshima,et al.  Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. , 1998, Blood.

[15]  K. Kohno,et al.  Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. , 1999, European journal of biochemistry.

[16]  L. Doyle,et al.  H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. , 1996, Cancer research.